JP2006511538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511538A5 JP2006511538A5 JP2004560402A JP2004560402A JP2006511538A5 JP 2006511538 A5 JP2006511538 A5 JP 2006511538A5 JP 2004560402 A JP2004560402 A JP 2004560402A JP 2004560402 A JP2004560402 A JP 2004560402A JP 2006511538 A5 JP2006511538 A5 JP 2006511538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- formula
- compound
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 11
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 10
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 208000031886 HIV Infections Diseases 0.000 claims 6
- 208000037357 HIV infectious disease Diseases 0.000 claims 6
- 241000282412 Homo Species 0.000 claims 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 3
- 229960000311 ritonavir Drugs 0.000 claims 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 1
- 229960001830 amprenavir Drugs 0.000 claims 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims 1
- 229960003277 atazanavir Drugs 0.000 claims 1
- DBMJZOMNXBSRED-OQLLNIDSSA-N bergomottin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC/C=C(C)/CCC=C(C)C DBMJZOMNXBSRED-OQLLNIDSSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 235000015201 grapefruit juice Nutrition 0.000 claims 1
- 229960001936 indinavir Drugs 0.000 claims 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 229960004438 mibefradil Drugs 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 1
- 229960000884 nelfinavir Drugs 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- BEMBRAMZGVDPMH-UHFFFAOYSA-N CCN(c1ncc(CCOc(c2c3cccc2)cc[n+]3[O-])cc11)c(nccc2)c2N(C)C1=O Chemical compound CCN(c1ncc(CCOc(c2c3cccc2)cc[n+]3[O-])cc11)c(nccc2)c2N(C)C1=O BEMBRAMZGVDPMH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43369002P | 2002-12-16 | 2002-12-16 | |
| PCT/EP2003/014224 WO2004054586A1 (en) | 2002-12-16 | 2003-12-15 | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006511538A JP2006511538A (ja) | 2006-04-06 |
| JP2006511538A5 true JP2006511538A5 (https=) | 2007-02-08 |
Family
ID=32595224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004560402A Pending JP2006511538A (ja) | 2002-12-16 | 2003-12-15 | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040152625A1 (https=) |
| EP (1) | EP1575595A1 (https=) |
| JP (1) | JP2006511538A (https=) |
| KR (1) | KR20050085681A (https=) |
| CN (1) | CN1726041A (https=) |
| AU (1) | AU2003296647A1 (https=) |
| BR (1) | BR0317095A (https=) |
| CA (1) | CA2510143A1 (https=) |
| EA (1) | EA200500894A1 (https=) |
| EC (1) | ECSP055854A (https=) |
| HR (1) | HRP20050557A2 (https=) |
| IL (1) | IL169099A0 (https=) |
| MX (1) | MXPA05005773A (https=) |
| NO (1) | NO20053455L (https=) |
| NZ (1) | NZ541187A (https=) |
| PL (1) | PL376900A1 (https=) |
| RS (1) | RS20050461A (https=) |
| UA (1) | UA81003C2 (https=) |
| WO (1) | WO2004054586A1 (https=) |
| ZA (1) | ZA200502947B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
| US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| WO2006114001A1 (en) * | 2005-04-27 | 2006-11-02 | Ambrilia Biopharma Inc. | Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
| ES2452718T3 (es) | 2005-11-30 | 2014-04-02 | Taimed Biologics, Inc. | Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación |
| CN1907138B (zh) * | 2006-08-11 | 2011-01-12 | 华南师范大学 | 一种沙田柚子汁提取物及其提取方法和应用 |
| CA2664118A1 (en) | 2006-09-21 | 2008-07-03 | Ambrilia Biopharma Inc. | Protease inhibitors |
| RU2544010C2 (ru) | 2009-02-27 | 2015-03-10 | Энанта Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
| PL2421527T3 (pl) * | 2009-04-25 | 2018-10-31 | F.Hoffmann-La Roche Ag | Sposoby poprawy właściwości farmakokinetycznych |
| EP2429568B1 (en) | 2009-05-13 | 2016-08-17 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3955920A1 (en) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| EP0986375A2 (en) * | 1997-04-07 | 2000-03-22 | Triangle Pharmaceuticals Inc. | Use of mkc-442 in combination with other antiviral agents |
| AU762349B2 (en) * | 1998-11-04 | 2003-06-26 | Pharmacia & Upjohn Company | Method for improving the pharmacokinetics of tipranavir |
| US6391919B1 (en) * | 2000-01-12 | 2002-05-21 | Bristol-Myers Squibb Pharma Company | Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors |
| TWI270547B (en) * | 2000-06-16 | 2007-01-11 | Boehringer Ingelheim Ca Ltd | Non-nucleoside reverse transcriptase inhibitors |
| ES2268499T3 (es) * | 2002-09-19 | 2007-03-16 | Boehringer Ingelheim (Canada) Ltd. | Inhibidores no nucleosidos de transcriptasa inveresa. |
-
2003
- 2003-12-15 WO PCT/EP2003/014224 patent/WO2004054586A1/en not_active Ceased
- 2003-12-15 EP EP03813119A patent/EP1575595A1/en not_active Withdrawn
- 2003-12-15 JP JP2004560402A patent/JP2006511538A/ja active Pending
- 2003-12-15 NZ NZ541187A patent/NZ541187A/en unknown
- 2003-12-15 AU AU2003296647A patent/AU2003296647A1/en not_active Abandoned
- 2003-12-15 MX MXPA05005773A patent/MXPA05005773A/es not_active Application Discontinuation
- 2003-12-15 UA UAA200507057A patent/UA81003C2/uk unknown
- 2003-12-15 EA EA200500894A patent/EA200500894A1/ru unknown
- 2003-12-15 PL PL376900A patent/PL376900A1/pl not_active Application Discontinuation
- 2003-12-15 KR KR1020057011003A patent/KR20050085681A/ko not_active Withdrawn
- 2003-12-15 BR BR0317095-0A patent/BR0317095A/pt not_active IP Right Cessation
- 2003-12-15 RS YUP-2005/0461A patent/RS20050461A/sr unknown
- 2003-12-15 CN CNA2003801063012A patent/CN1726041A/zh active Pending
- 2003-12-15 US US10/736,301 patent/US20040152625A1/en not_active Abandoned
- 2003-12-15 HR HR20050557A patent/HRP20050557A2/xx not_active Application Discontinuation
- 2003-12-15 CA CA002510143A patent/CA2510143A1/en not_active Abandoned
-
2005
- 2005-04-12 ZA ZA200502947A patent/ZA200502947B/en unknown
- 2005-06-09 IL IL169099A patent/IL169099A0/en unknown
- 2005-06-15 EC EC2005005854A patent/ECSP055854A/es unknown
- 2005-07-15 NO NO20053455A patent/NO20053455L/no not_active Application Discontinuation
-
2007
- 2007-10-25 US US11/923,699 patent/US20080096832A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511538A5 (https=) | ||
| JP2011528713A5 (https=) | ||
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| JP2021521118A5 (https=) | ||
| WO2007070677A3 (en) | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease | |
| JP2008523153A5 (https=) | ||
| US20080096832A1 (en) | Method for Improving the Pharmacokinetics of an NNRTI | |
| JP2010532372A5 (https=) | ||
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| NO20076595L (no) | Behandling av leversykdommer hvor jern spiller en rolle i patogenesen | |
| ES3060114T3 (https=) | ||
| JP2017514911A5 (https=) | ||
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JPWO2023054732A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| JP2007504168A5 (https=) | ||
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales | |
| JP2023531675A5 (https=) | ||
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| KR102512494B1 (ko) | 의약 | |
| JP2023531930A5 (https=) | ||
| JP2024525164A5 (https=) | ||
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| JP2007536359A5 (https=) |